THU0184 PREVIOUSLY UNKNOWN GASTRO-INTESTINAL ADVERSE DRUG REACTIONS ATTRIBUTED TO ETANERCEPT

Background: Although an increased risk of inflammatory bowel disease (IBD) during etanercept (ETN) use is included in the product information of ETN, no other gastro-intestinal (GI-)adverse drug reactions (ADRs) are described. This is in contrast with other TNFα-inhibitors such as adalimumab (ADA) and infliximab, as these are associated with various GI-ADRs such as nausea and abdominal pain. Objectives: To identify the proportion and type of...